Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment. Verubecestat is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1... In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat.
- Mechanism
- Curator reviewed
The amyloid hypothesis asserts that the formation of amyloid peptides that lead to amyloid plaque deposits in the brain is a primary contributor to the underlying cause of Alzheimer's disease. BACE is believed to be a key enzyme in the production of amyloid β peptide. Evidence suggests that inhibiting BACE decreases the production of amyloid β peptide and may therefore reduce amyloid plaque formation and modify disease progression.
- Formula / weight
- C17H17F2N5O3S · 409.41 g/mol (avg)
- Code names
- MK-8931 · SCH-900931
Resolves to
YHYKUSGACIYRML-KRWDZBQOSA-NSMILESCN1C(N)=N[C@@](C)(CS1(=O)=O)C1=CC(NC(=O)C2=CC=C(F)C=N2)=CC=C1FWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Verubecestat, and which of those have an active Phase 3 trial?